Study of Everolimus as Maintenance Therapy for Metastatic NEC With Pulmonary or Gastroenteropancreatic Origin
Status:
Recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
Cisplatin and Etoposide is the standard of care in NEC originating from the gastro-intestinal
tract and lung, based on retrospective studies.
Nevertheless the prognosis of this group of patients is still poor with median survival of
less than 20 months.
Everolimus is an mammilian target of rapamycin (mTOR) inhibitor that has been demonstrated to
be active in patients with well and moderately differentiated primitive neuroectodermal tumor
(pNET).
Recently, the Investigators demonstrated that the mammilian target of rapamycin (mTOR)
pathway is overexpressed in NEC.
Based on the activity of Everolimus in the treatment of patients with well and moderately
differentiated p-NET and on the evidence that even poorly differentiated forms express the
pathway of m-TOR is conceivable that Everolimus could be active even in NEC.